Divi's Laboratories Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company has consistently been profitable over the last 5 years
- Latest quarter profit grew 65.5% YoY, showing strong momentum
- Company has been maintaining a healthy dividend payout of 31.0%
- Company has a consistent dividend-paying track record
- Company generates healthy free cash flow
CONS
- Company has delivered a poor profit growth of 5.3% over past five years
- Stock is trading at 9.4x its book value
- Expensive relative to growth - PEG of 7.0
- Rich enterprise valuation - EV/EBITDA of 39.0x
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| BIOCON | 390.95 | 128.63 | 63712.89 | 0.13 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,778 | 1,909 | 1,855 | 2,303 | 2,118 | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 | |
| 1,274 | 1,430 | 1,366 | 1,572 | 1,496 | 1,622 | 1,576 | 1,699 | 1,681 | 1,827 | 1,714 | 1,897 | 1,964 | |
| Operating Profit | 504 | 479 | 489 | 731 | 622 | 716 | 743 | 886 | 729 | 888 | 890 | 934 | 1,116 |
| OPM % | 28.35% | 25.09% | 26.36% | 31.74% | 29.37% | 30.62% | 32.04% | 34.27% | 30.25% | 32.71% | 34.18% | 32.99% | 36.23% |
| 81 | 86 | 95 | 79 | 79 | 106 | 82 | 86 | 119 | 145 | 14 | 155 | 64 | |
| Interest | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 3 | 8 | 6 | 6 | 6 |
| Depreciation | 93 | 95 | 95 | 95 | 97 | 99 | 99 | 107 | 112 | 113 | 118 | 120 | 133 |
| Profit before Tax | 492 | 469 | 489 | 713 | 604 | 722 | 726 | 864 | 733 | 912 | 780 | 963 | 1,180 |
| Tax % | 27.64% | 25.80% | 26.79% | 24.54% | 28.81% | 29.36% | 18.87% | 23.38% | 25.65% | 24.45% | 25.26% | 22.01% | 23.56% |
| Net Profit | 0 | 0 | 0 | 0 | 430 | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 |
| 13.41 | 13.11 | 13.50 | 20.25 | 16.20 | 19.20 | 22.20 | 24.93 | 20.49 | 25.97 | 21.98 | 28.31 | 33.95 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4,064 | 3,891 | 4,946 | 5,394 | 6,969 | 8,960 | 7,767 | 7,845 | 9,360 | 10,560 | 11,230 | |
| 2,617 | 2,629 | 3,073 | 3,571 | 4,108 | 5,079 | 5,398 | 5,639 | 6,393 | 7,118 | 7,402 | |
| Operating Profit | 1,447 | 1,263 | 1,873 | 1,823 | 2,861 | 3,881 | 2,369 | 2,206 | 2,967 | 3,442 | 3,828 |
| OPM % | 35.61% | 32.45% | 37.87% | 33.80% | 41.05% | 43.32% | 30.50% | 28.12% | 31.70% | 32.59% | 34.09% |
| 75 | 113 | 156 | 190 | 63 | 116 | 345 | 339 | 354 | 433 | 378 | |
| Interest | 3 | 2 | 5 | 7 | 2 | 2 | 2 | 4 | 3 | 24 | 26 |
| Depreciation | 123 | 142 | 169 | 186 | 256 | 312 | 343 | 378 | 402 | 463 | 484 |
| Profit before Tax | 1,395 | 1,231 | 1,855 | 1,819 | 2,666 | 3,684 | 2,369 | 2,163 | 2,916 | 3,388 | 3,835 |
| Tax % | 24.00% | 28.78% | 27.08% | 24.34% | 25.57% | 19.63% | 23.01% | 26.03% | 24.86% | 24.20% | 23.73% |
| Net Profit | 1,060 | 877 | 1,353 | 1,377 | 1,984 | 2,960 | 1,824 | 1,600 | 2,191 | 2,568 | 2,925 |
| EPS | 39.95 | 33.04 | 50.96 | 51.85 | 74.75 | 111.52 | 68.69 | 60.38 | 82.68 | 96.91 | — |
| Dividend Payout % | 25.03% | 30.27% | 31.40% | 30.85% | 26.76% | 26.90% | 43.59% | 49.69% | 36.28% | 30.96% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 11%
- 5 Years:
- 9%
- 3 Years:
- 11%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 9%
- 5 Years:
- 5%
- 3 Years:
- 12%
STOCK PRICE CAGR
- 10 Years:
- 22%
- 5 Years:
- 13%
- 3 Years:
- 35%
- 1 Year:
- 55%
RETURN ON EQUITY
- 10 Years:
- 19%
- 5 Years:
- 17%
- 3 Years:
- 15%
- Last Year:
- 16%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| 5,304 | 5,872 | 6,904 | 7,257 | 9,242 | 11,675 | 12,714 | 13,518 | 14,916 | 16,708 | |
| 36 | 63 | 106 | 38 | 4 | 3 | 3 | 2 | 4 | 679 | |
| Trade Payables | 446 | 411 | 492 | 591 | 763 | 796 | 762 | 824 | 910 | 1,211 |
| 1,590 | 1,948 | 1,240 | 1,486 | 1,325 | 2,092 | 1,331 | 1,540 | 1,834 | 2,227 | |
| Total Liabilities | 7,429 | 8,347 | 8,795 | 9,425 | 11,387 | 14,619 | 14,863 | 15,937 | 17,717 | 20,878 |
| 1,559 | 1,996 | 2,088 | 2,782 | 3,704 | 4,325 | 4,722 | 4,739 | 5,442 | 6,528 | |
| Capital Work in Progress | 444 | 120 | 492 | 920 | 711 | 470 | 212 | 778 | 1,022 | 2,113 |
| 1,631 | 1,889 | 1,946 | 971 | 0 | 72 | 77 | 82 | 65 | 69 | |
| 1,320 | 1,351 | 1,772 | 1,864 | 2,145 | 2,829 | 3,000 | 3,184 | 3,236 | 3,954 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,156 | 2,731 | 2,984 | |
| Cash & Bank | 79 | 112 | 115 | 123 | 2,156 | 2,819 | 4,214 | 3,980 | 3,715 | 3,414 |
| 2,396 | 2,879 | 2,382 | 2,766 | 2,671 | 4,105 | 2,638 | 1,018 | 1,506 | 1,816 | |
| Total Assets | 7,429 | 8,347 | 8,795 | 9,425 | 11,387 | 14,619 | 14,863 | 15,937 | 17,717 | 20,878 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,452 | 1,044 | 1,439 | 1,661 | 2,591 | 2,553 | 2,932 | 1,261 | 1,653 | 2,738 | |
| Cash from Investing | -1,140 | -478 | -685 | -83 | 75 | -2,195 | -2,707 | -269 | -804 | -2,219 |
| Cash from Financing | 2 | -314 | -246 | -1,091 | -35 | -532 | -797 | -799 | -799 | -804 |
| 13 | -17 | 23 | 41 | 1,987 | -816 | -1,045 | 193 | 50 | -285 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-12 - Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-10 - Divi's Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 10, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
2026-08-06 - Divi's Laboratories Limited has informed the Exchange about Transcript
2026-08-03 - Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-01 - Divi's Laboratories Limited has informed the Exchange about Link of Recording
2026-08-01 - Divi's Laboratories Limited has informed the Exchange about change in Senior Management.
2026-08-01 - Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-31 - Divi's Laboratories Limited has informed the Exchange about Retirement of Senior Management Personnel.
2026-07-24 - Divi's Laboratories Limited has informed the Exchange about Schedule of meet
News
Recent coverage and analyst commentary for DIVISLAB
Loading news…
AI Stock Analyst
Divi's Laboratories Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account